Because no ASCVD outcomes as defined above were reported for the PCSK9 mAb alirocumab trial, ODYSSEY OUTCOMES [27], a sensitivity analysis with the trial’s primary endpoint of death, nonfatal MI, fatal or nonfatal stroke, or hospitalized unstable angina is reported in S3 Fig. Here, PCSK9 is linked to angina pectoris.